{"filing":{"accession_number":"0001493152-26-036408","cik":"0000946644","ticker":"AIM","company_name":"AIM ImmunoTech Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-07-31","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/form8-k.htm"},"events":[{"id":24696,"run_id":22392,"accession_number":"0001493152-26-036408","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses entry into a Proposal Agreement with Sterling Pharma Solutions for manufacturing of drug substance precursors (PolyI and Poly C12U) for Ampligen at an estimated cost of $1.5 million over 12 months, with anticipated use in ongoing and future clinical trials including a potential Phase 3 trial for metastatic pancreatic cancer. This is a material operational/strategic contract related to the Company's clinical development pipeline, but does not fit the specific categories of debt issuance, M\u0026A activity, or other named event types. Item 5.08 regarding shareholder director nominations is routine administrative disclosure.","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":25346,"accession_number":"0001493152-26-036408","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into a Proposal Agreement with Sterling Pharma Solutions for manufacturing of drug substance precursors (PolyI and Poly C12U) for Ampligen at an estimated cost of $1.5 million over 12 months, with anticipated use in ongoing and future clinical trials including a potential Phase 3 trial for metastatic pancreatic cancer. This is a material operational/strategic contract related to the Company's clinical development pipeline, but does not fit the specific categories of debt issuance, M\u0026A activity, or other named event types. Item 5.08 regarding shareholder director nominations is routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:39:43.826460+00:00","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-08-06"}]}